Therapeutic area intelligence for GLP-1 Receptor Agonist with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 2

Companies

Eli Lilly →

Pfizer →

Assets

Berobenatide →

Tirzepatide →

Recent signals(3)

CompetitiveJuly 19, 2026

Eli Lilly's LY3457263 Trial in Type 2 Diabetes Shows Potential Against Semaglutide and Tirzepatide

Eli Lilly is conducting a trial to evaluate LY3457263 against placebo in type 2 diabetes patients on semaglutide or tirzepatide.

ClinicalJune 28, 2026

Tirzepatide Evaluated for Cannabis Use Disorder in Proof-of-Concept Study

A proof-of-concept study is underway to evaluate Tirzepatide for treating Cannabis Use Disorder (CUD).

ClinicalJune 16, 2026

Pfizer's Berobenatide Shows Promising Phase 2b Results for Monthly Dosing in Obesity Management

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Diabetes →

Obesity →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.